WallStreetZenWallStreetZen

NASDAQ: BIOC
Biocept Inc Stock

$0.24-0.11 (-31.43%)
Updated Mar 17, 2023
BIOC Price
$0.24
Fair Value Price
$1.30
Market Cap
$4.03M
52 Week Low
$0.24
52 Week High
$2.43
P/E
-0.24x
P/B
0.15x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$50.12M
Earnings
-$16.54M
Gross Margin
31.8%
Operating Margin
-32.07%
Profit Margin
-33%
Debt to Equity
0.86
Operating Cash Flow
-$7M
Beta
0.41
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BIOC Overview

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIOC ($0.24) is undervalued by 81.79% relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIOC ($0.24) is significantly undervalued by 81.79% relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIOC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOC due diligence checks available for Premium users.

Be the first to know about important BIOC news, forecast changes, insider trades & much more!

BIOC News

Valuation

BIOC fair value

Fair Value of BIOC stock based on Discounted Cash Flow (DCF)
Price
$0.24
Fair Value
$1.30
Undervalued by
81.48%
BIOC ($0.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOC ($0.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIOC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.24x
Industry
32.57x
Market
21.81x

BIOC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
4.1x
BIOC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIOC's financial health

Profit margin

Revenue
$5.6M
Net Income
-$5.5M
Profit Margin
-99.2%
BIOC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIOC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$51.1M
Liabilities
$23.6M
Debt to equity
0.86
BIOC's short-term assets ($36.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOC's short-term assets ($36.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.1M
Investing
-$356.0k
Financing
-$476.0k
BIOC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BIOC vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
BIOC$4.03M-31.59%-0.24x0.15x
MOTS$4.05M-2.90%-0.09x5.32x
OPGN$3.95M+6.52%-0.08x0.28x
TTOO$3.62M-6.60%-0.03x-0.11x
HTGM$2.60M-4.73%-0.10x2.15x

Biocept Stock FAQ

What is Biocept's quote symbol?

NASDAQ: BIOC) Biocept trades on the NASDAQ under the ticker symbol BIOC. Biocept stock quotes can also be displayed as NASDAQ: BIOC.

If you're new to stock investing, here's how to buy Biocept stock.

What is the 52 week high and low for Biocept (NASDAQ: BIOC)?

(NASDAQ: BIOC) Biocept's 52-week high was $2.43, and its 52-week low was $0.24. It is currently -90.29% from its 52-week high and at its 52-week low.

How much is Biocept stock worth today?

(NASDAQ: BIOC) Biocept currently has 17,058,770 outstanding shares. With Biocept stock trading at $0.24 per share, the total value of Biocept stock (market capitalization) is $4.03M.

Biocept stock was originally listed at a price of $8,460.02 in Feb 5, 2014. If you had invested in Biocept stock at $8,460.02, your return over the last 9 years would have been -100%, for an annualized return of -68.81% (not including any dividends or dividend reinvestments).

How much is Biocept's stock price per share?

(NASDAQ: BIOC) Biocept stock price per share is $0.24 today (as of Mar 17, 2023).

What is Biocept's Market Cap?

(NASDAQ: BIOC) Biocept's market cap is $4.03M, as of Mar 20, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biocept's market cap is calculated by multiplying BIOC's current stock price of $0.24 by BIOC's total outstanding shares of 17,058,770.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.